Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sebela Reports Positive Phase 3 TRIUMpH Results for Tegoprazan in GERD
Details : BLI5100 (tegoprazan) is a novel agent and member of a class of oral medications known as P-CABs. It is being evaluated in late-stage clinical trial studies for the treatment of GERD.
Product Name : BLI5100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable